Loading clinical trials...
Loading clinical trials...
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Conditions
Interventions
Trametinib
Hydroxychloroquine
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
February 15, 2022
Primary Completion Date
May 11, 2022
Completion Date
December 31, 2022
Last Updated
August 21, 2023
NCT07146646
NCT06048133
NCT06252753
NCT06230471
NCT06653192
NCT03801083
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions